Current Report · Items 8.01 · 8-K
Accustem Sciences Inc
ACUTOTCEQUITYCurrent
Other Events
Item Other 8.01 Events. Accustem Sciences Inc.’s (the “Company”) MSC test (MicroRNA Signature Classifier) is a non-invasive blood-based assay designed to assess the risk of lung cancer in people who qualify for low-dose computed tomography (LDCT) screening or have an indeterminate pulmonary nodule detected via imaging.…
Company context
Current securities
Historical securities (1)
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item Other
8.01 Events.
Accustem
Sciences Inc.’s (the “Company”) MSC test (MicroRNA Signature Classifier) is a non-invasive blood-based assay designed
to assess the risk of lung cancer in people who qualify for low-dose computed tomography (LDCT) screening or have an indeterminate pulmonary
nodule detected via imaging. It analyzes a panel of 24 circulating microRNAs (miRNAs) in plasma to classify nodules as Low or High Risk
for malignancy. This helps clinicians more accurately understand a patient’s cancer risk, potentially reducing unnecessary invasive
procedures (e.g., biopsies or surgery) for benign nodules while prioritizing those at higher risk for further evaluation.
In
order to establish reimbursement for the MSC test, the Company has submitted an application for a local coverage determination with Novitas
Solutions (“Novitas”), a Medicare Administrative Contractor (MAC) for the Centers for Medicare & Medicaid Services (CMS)
for the JL region, which includes the District of Columbia, Delaware, Maryland, New Jersey and Pennsylvania. As part of this submission
process Novitas has informed the Company that it has determined that the application is complete and valid and will now enter the review
queue.
-2-